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INTRODUCTION
THE CAUSE OF SELECTIVE DOPAMINERGIC DEGENERATION inthe substantia nigra of Parkinson’s disease (PD) patients
remains unknown; however, research has linked cell death in
PD to oxidative stress (for review, see 10) and mitochondrial
dysfunction (6, 43, 44). Direct effects of reactive oxygen
species (ROS), including increased lipid peroxidation, pro-
tein carbonyls, and DNA damage in PD brain, have been ob-
served (2). Increased iron and significant decreases in the
major antioxidant, glutathione (GSH), which also promotes
oxidative stress, have also been observed in PD (25).
The relationship between oxidative stress and dopamine
(DA) oxidation in degeneration has provided a link between the
selective vulnerability of DA neurons and PD. Increased DA
metabolism, by both monoamine oxidase (MAO) and DA oxi-
dation into DA quinone (DAQ), will cause increased ROS pro-
duction, which may lead to oxidation of protein, DNA, and
lipids (16, 18, 20, 32). In addition to ROS, the electron-defi-
cient DAQ readily reacts with cellular nucleophiles, including
reduced sulfhydryl groups, located on free cysteine residues,
GSH, and proteins (14, 15, 56). Modification of free thiols and
GSH can lead to the reduction in the amount of antioxidants
available to protect the cells from oxidative stress. In addition,
free cysteinyl-DA conjugates can be further oxidized to form 7-
(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-
carboxylic acid (DHBT-1), a mitochondrial toxin (29). DAQ
modification of proteins lead to the formation of covalently
bound DA-protein conjugates, often on cysteinyl residues (21).
Many vital proteins contain cysteine residues at their active
sites, and therefore modification may alter the function of these
proteins, leading to inactivation and possibly cell death. Both
in vitro (16) and in vivo (13, 22) studies support the hypothesis
that exposure to DA increases protein cysteinyl-catechol levels,
and in vivo causes selective damage to DA terminals (39). Pro-
tein modification by DAQ has also been observed following the
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ABSTRACT
Deficiencies in Complex I have been observed in Parkinson’s disease (PD) patients. Systemic exposure to
rotenone, a Complex I inhibitor, has been shown to lead to selective dopaminergic cell death in vivo and toxic-
ity in many in vitro models, including dopaminergic cell cultures. However, it remains unclear why rotenone
seems to affect dopaminergic cells more adversely. Therefore, the role of dopamine (DA) in rotenone-induced
PC12 cell toxicity was examined. Rotenone (1.0 µM) caused significant toxicity in differentiated PC12 cells,
which was accompanied by decreases in ATP levels, changes in catechol levels, and increased DA oxidation. To
determine whether endogenous DA makes PC12 cells more susceptible to rotenone, cells were treated with the
tyrosine hydroxylase inhibitor -methyl-p-tyrosine (AMPT) to reduce DA levels prior to rotenone exposure,
and then cell viability was measured. No changes in rotenone-induced toxicity were observed with or without
AMPT treatment. However, a potentiation of toxicity was observed following coexposure of PC12 cells to
rotenone and methamphetamine. To determine whether this effect was due to DA, PC12 cells were depleted
of DA prior to methamphetamine and rotenone cotreatment, resulting in a large attenuation in toxicity.
These findings suggest that DA plays a role in rotenone-induced toxicity and possibly the vulnerability of DA
neurons in PD. Antioxid. Redox Signal. 7, 630–638.
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dopaminergic toxins methamphetamine (METH) (28) and 1-
methyl-4-phenylpyridinium (MPP+) (55), indicative of endoge-
nous DA oxidation. The presence of neuromelanin in the brain
and cysteinyl-catechol conjugates in PD brain lysates (53) sug-
gests that DA oxidation occurs in vivo. Therefore, the presence
of DA in the cytoplasm, especially in a reduced antioxidant en-
vironment, will add to the oxidative stress of a cell through ROS
and DAQ production and through the subsequent oxidation of
important biomolecules, making dopaminergic neurons in the
substantia nigra more susceptible to cell death.
Impairment of mitochondrial function is also likely to
contribute to oxidative stress and cell death in PD. The link
between Complex I inhibition and PD was first identified after
the dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) was discovered to be a potent Complex I in-
hibitor. Further studies revealed that impaired mitochondrial
function, in the form of a Complex I deficiency, occurs in PD
in the substantia nigra (35, 42) and systemically in platelets
and muscle (6, 52). The role of Complex I inhibition in PD has
been expanded through experimentation with pesticides and
toxins that inhibit Complex I, including MPTP, paraquat, and
rotenone, all of which cause selective DA degeneration (for
reviews, see 11, 12, 17). The selective toxicity of both MPTP
and paraquat is due to their similar structure, which makes
them substrates for the DA transporter (DAT) (34, 37, 51).
Rotenone, however, is not a substrate for DAT. It is lipophilic
and can cross membranes of all cells easily. In vivo studies
have shown that chronic, systemic administration of rotenone
produces dopaminergic degeneration and Lewy body-like cy-
toplasmic inclusions, which closely mimic the pathology of
PD (5), although less selective effects have also been observed
(23). The systemic rotenone model does represent both the
central and peripheral inhibition of Complex I as seen in PD,
which leads to nigrostriatal dopaminergic degeneration (5), -
synuclein aggregation (48), and glial activation (49). Rotenone
treatment also functions as an effective PD model in vitro, re-
sulting in toxicity to dopaminergic cells (19), increasing oxida-
tive stress (47), and decreasing proteasome activity (46). 
Partial inhibition of Complex I has been shown to increase
mitochondrial production of ROS (38, 57), which may be the
precipatory event in toxicity models. However, the basis for
rotenone-induced selective toxicity to dopaminergic neurons
remains ambiguous. The increased oxidative stress within
dopaminergic neurons, due to DA metabolism and oxidation,
combined with a Complex I inhibition-induced ROS pro-
duction may lead to cell death by overloading the oxidative
capacity of dopaminergic cells. Therefore, in this study we
sought to investigate whether DA was involved in rotenone-
induced toxicity in PC12 cells. We found that DA depletion
prior to toxin exposure did not protect against rotenone-
induced toxicity. However, rotenone toxicity was potentiated
by METH-induced increases in cytoplasmic DA in PC12 cells. 
MATERIALS AND METHODS
Chemicals
Cell culture media, Dulbecco’s modified Eagle medium
(DMEM; GIBCO brand), fetal bovine serum (HyClone
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brand), and horse serum (HyClone brand) were purchased
from Invitrogen (Carlsbad, CA, U.S.A.). Rotenone was
obtained from ICN Biomedicals (Costa Mesa, CA, U.S.A.),
-methyl-p-tyrosine (AMPT) from Fluka (Ronkonkoma, NY,
U.S.A.), and nerve growth factor (NGF) from BD Bioscience
(San Diego, CA, U.S.A.) and Accurate Chemical (Westbury,
NY, U.S.A.). All other reagents were purchased from Sigma
(St. Louis, MO, U.S.A.).
PC12 cell culture
PC12 cells, a rat adrenal pheochromocytoma-derived cell
line, were differentiated in DMEM supplemented with 1%
fetal bovine serum, 1% horse serum, and 100 ng/ml NGF for
3 days. Cells were then treated with rotenone [dissolved in di-
methyl sulfoxide (DMSO)] and/or methamphetamine, in dif-
ferentiation media for 2–48 h. Control cultures underwent a
medium change at the same time as rotenone-treated cultures.
Cell viability was determined by cell counting using the try-
pan blue exclusion method. Vehicle (DMSO) had no effect on
cell viability (data not shown).
Depletion of cellular DA
DA levels were depleted using the tyrosine hydroxylase
(TH) inhibitor AMPT. AMPT was added to the differentiating
media in concentrations of 100, 300, or 1,000 µM. For subse-
quent experiments in which DA levels were depleted, 1,000
µM AMPT was added 3 days prior to, and then sustained dur-
ing, rotenone treatment.
Biochemical analysis
For DA and 3,4-dihydroxyphenylacetic acid (DOPAC)
measurements, PC12 cells were collected following treat-
ment, and the protein was acid-precipitated in 0.1 M perchlo-
ric acid and centrifuged at 14,000 g for 25 min. An aliquot
of the supernatant was extracted with alumina, and injected
into an HPLC system containing an ESA (Chelmsford, MA,
U.S.A.) Coulochem II coulometric detector (+280 V). Pro-
tein cysteinyl catechols [protein cys-DA, cys-DOPAC, and
cysteinyl-3,4-dihydroxyphenylalanine (cys-DOPA)] were
measured following hydrolysis of protein in 6 M HCl con-
taining 1 mg/ml bovine serum albumin, as described previ-
ously (21). Hydrolyzed protein samples were extracted with
alumina prior to analysis on HPLC with a Waters 460 am-
perometric detector set at an oxidizing potential of 0.6 V.
Peaks for catechols and cysteinyl-catechols were identified
and quantified by comparison with standards.
ATP measurement
Following exposure to DA, protein from PC12 cells was
precipitated in 2% trichloroacetic acid and centrifuged at
14,000 g for 25 min. A luciferase-based assay was used to mea-
sure ATP levels in an aliquot of the resulting supernatant (40).
A Monolight 3010 luminometer (Pharmingen, San Diego, CA,
U.S.A.) was used to measure the light output resulting after an
aliquot of diluted cell sample, 30 mM HEPES, pH 7.75, and
Enlighten luciferase/luciferin reagent (Promega, Madison, WI,
U.S.A.) were mixed in a cuvette. Protein amounts were deter-
mined by the Bradford assay (7).
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Statistical analysis
Differences among group means were determined by
ANOVA followed by post-hoc Student’s t test with signifi-
cance determined at p < 0.05.
RESULTS
Rotenone-induced PC12 cell toxicity
Previous studies have shown the mitochondrial Complex I
inhibitor rotenone to be toxic to DA-containing cells, such as
undifferentiated PC12 cells (19), SH-SY5Y cells (46), and
primary mesencephalic cultures (30). To evaluate the suscep-
tibility of differentiated PC12 cells to rotenone toxicity, cell
viability was determined using trypan blue exclusion, follow-
ing 48 h of rotenone exposure at concentrations ranging from
0.5 µM to 20 µM (Fig. 1). Rotenone treatment for 48 h signif-
icantly decreased the number of viable cells, from 37% to
70% as compared with time-matched control cells, at all
concentrations measured (Fig. 1). Future experiments used
either the 0.5 µM or 1 µM rotenone concentration, because
these were the lowest concentrations that caused significant
amounts of cell death.
Rotenone reduced ATP levels in PC12 cells
Rotenone exposure inhibits mitochondrial Complex I and
in part the electron transport chain, potentially reducing ATP
synthesis. Previous studies have shown that rotenone treat-
ment in SK-N-MC human neuroblastoma cells led to a dose-
dependent loss in ATP (47). Therefore, to determine whether
the rotenone concentrations that caused decreases in viability
also led to reductions in ATP level, we measured ATP levels
in differentiated PC12 cells treated with 1 µM rotenone, for
12–48 h (Fig. 2). We observed significant decreases in ATP
levels following 12, 24, and 48 h of rotenone exposure, rang-
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ing from 25% to 65% as compared with time-matched
control levels (Fig. 2). The greatest depletion occurred after
48 h of rotenone exposure.
Effects of rotenone on catechol levels
Rotenone has previously been shown to cause cate-
cholamine release in PC12 cells (54); therefore, we wanted to
determine whether cellular catecholamine levels were af-
fected by rotenone. DOPA, DA, and DOPAC amounts were
measured in differentiated PC12 cells treated with 1 µM
rotenone for 2–48 h and compared with time-matched control
levels (Fig. 3). DOPA levels were significantly increased
from control (+130%) following 48 h of 1 µM rotenone treat-
ment. In contrast, DA levels were significantly lower than
control following 6–24 h of 1 µM rotenone treatment, ranging
from 18% to 25% of time-matched control levels. How-
ever, the greatest decrease was observed in DOPAC levels,
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FIG. 1. Concentration curve for rotenone toxicity. Differ-
entiated PC12 cells were treated for 48 h with increasing
concentrations of rotenone dissolved in DMSO. The number of
viable cells was counted using trypan blue exclusion. Data are
expressed as mean % control viable cells ± SEM (n = 3–4).
*Significantly different from control, p < 0.05.
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FIG. 2. ATP levels in PC12 cells following rotenone expo-
sure. Differentiated PC12 cells were treated with 1 µM rotenone
for 12, 24, or 48 h. ATP levels were measured from PC12 cell
lysate in a luminometer. Control ATP levels were 13.0 ± 1.5
nmol/mg of protein. Data are expressed as mean % control ±
SEM (n = 4). *Statistically significant from control, p < 0.05.
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FIG. 3. Catechol levels following rotenone exposure. Dif-
ferentiated PC12 cells were treated with 1 µM rotenone for
2–48 h. DA, DOPAC, and DOPA levels were determined using
HPLC with electrochemical detection. Average control DA lev-
els were 2.0 ± 0.2 nmol/mg of protein. Average control DOPAC
levels were 48 ± 4.9 pmol/mg of protein. Average control
DOPA levels were 511 ± 51 pmol/mg of protein. Data are ex-
pressed as mean % control ± SEM (n = 4–5). *Statistically sig-
nificant from control, p < 0.05.
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which were significantly lower (33% to 68%) than con-
trol at all time points observed, following 1 µM rotenone
treatment. The sustained low levels of DOPAC suggested that
rotenone exposure might alter MAO activity, the enzyme that
metabolizes DA to DOPAC. To evaluate this possibility, we
treated isolated rat brain mitochondria with 1 µM rotenone,
exposed the mitochondria to 50 µM DA, and measured DA
metabolites using HPLC. The rates of DA metabolism were
similar in rotenone-treated and untreated mitochondria, sug-
gesting that this was not a direct effect of rotenone on MAO
activity (data not shown).
Effect of rotenone on DA oxidation
Rotenone inhibits mitochondrial Complex I, leading to
ROS production (38, 57). Increased ROS is likely to lead
to increased DA oxidation and DAQ formation in DA-
containing neurons, which may additionally contribute to the
rotenone-induced toxicity. As a measure of DA oxidation and
catechol oxidation in general, we evaluated the formation of
protein cysteinyl-catechols in PC12 cells treated with 1 µM
rotenone (Fig. 4). Protein from rotenone-treated cells was
acid-precipitated and hydrolyzed to break up the protein
into its amino acid components. Protein cysteinyl-DA and
cysteinyl-DOPAC levels were then measured using HPLC.
Protein cys-DA levels were increased above control (+150%)
following 48 h of rotenone treatment (Fig. 4). Protein cys-
DOPAC levels were also increased significantly from control
(+120–140% of control) after a 12–48-h rotenone treatment
(Fig. 4), suggesting that rotenone treatment leads to increased
DA and DOPAC oxidation, resulting in protein modification
in PC12 cells.
DA depletion does not protect PC12 cells
from rotenone-induced toxicity
Because DA may make cells more susceptible to cell death
due to the formation of reactive DA metabolites, we examined
whether the presence of DA makes PC12 cells more suscepti-
ble to rotenone-induced toxicity. To evaluate this initially, DA
was depleted in PC12 cells using the TH inhibitor, AMPT. As
TH is the rate-limiting step in DA synthesis, blocking TH will
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stop DOPA, the DA precursor, from being produced, and thus
depletes cells of DA and its metabolite, DOPAC. PC12 cells
were treated with increasing concentrations of the TH in-
hibitor, AMPT (0–1,000 µM) during the 3-day differentiation
period (Fig. 5). Results showed that DA, DOPAC, and DOPA
levels were all significantly decreased in a concentration-
dependent manner following AMPT treatment (Fig. 5). At the
highest concentration (1,000 µM AMPT), DA levels were only
7.5% of control and DOPAC and DOPA levels were non-
detectable. AMPT (1,000 µM) treatment alone had no effect
on PC12 cell viability (Fig. 6), and therefore was chosen for
all subsequent DA depletion experiments.
The effect of DA depletion on rotenone toxicity was deter-
mined by pretreatment with 1,000 µM AMPT for 72 h, fol-
lowed by 1 µM rotenone or vehicle plus AMPT for an addi-
tional 48 h. Rotenone treatment alone led to a 60% decrease
in viable cells. However, AMPT plus rotenone showed a simi-
lar decrease in cell viability (60%), which did not differ
from the rotenone-alone treated cells (Fig. 6).
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FIG. 4. Protein cysteinyl-catechol levels following rotenone
exposure. Differentiated PC12 cells were treated with 1 µM
rotenone for 2–48 h. Protein cysteinyl-DA and protein cys-
teinyl-DOPAC levels were determined using HPLC with elec-
trochemical detection. Data are expressed as mean % control ±
SEM (n = 4–6). *Statistically significant from control, p < 0.05.
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FIG. 5. Effect of AMPT on catechol levels. PC12 cells were
treated with 0–1,000 µM AMPT, a TH inhibitor, for 72 h during
differentiation. DA, DOPAC, and DOPA levels were measured
using HPLC with electrochemical detection. Data are expressed
as means ± SEM (n = 4). *Statistically significant from control,
p < 0.05.
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FIG. 6. PC12 cell viability following DA depletion and
rotenone exposure. PC12 cells were treated with 1 mM AMPT
or control medium for 72 h, followed by 1 µM rotenone or vehi-
cle for 48 h. Cell viability was then determined using trypan blue
exclusion. Data are expressed as mean % control ± SEM (n = 4).
*Statistically significant from control, p < 0.05.
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METH potentiated rotenone-induced toxicity
in PC12 cells
PC12 cells contain both synaptic-like vesicles and large
dense-core vesicles (36), which comprise a large storage ca-
pacity for DA, and thus, much of the DA would be adequately
sequestered away from any rotenone-produced ROS. Because
DA depletion did not attenuate rotenone-induced toxicity,
we sought to determine whether increasing cytoplasmic DA
by treatment with METH would potentiate rotenone-induced
toxicity. Previous studies in primary cultures have shown that
rotenone potentiated toxicity induced by amphetamine, which
releases DA from vesicles into the cytoplasm (31). First, to
confirm the mobilization of intracellular DA stores in PC12
cells following METH treatment, we exposed differentiated
PC12 cells to control medium, 0.5 µM rotenone, 0.5 mM
METH, or 0.5 µM rotenone plus 0.5 mM METH in medium
for 24 h and then measured cellular catechol levels (Fig. 7A).
METH treatment alone did not affect DOPA levels. However,
there was a significant increase in DOPA levels to 217% and
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310% of control in the rotenone- and rotenone plus METH-
treated cells, respectively. DOPAC levels were decreased to
55%, 24%, and 72% as compared with control follow-
ing METH, rotenone, and rotenone plus METH treatment,
respectively. DA levels were not affected by rotenone treat-
ment alone, but were significantly decreased 83% from
control following 24 h of METH, and 73% after a rotenone
plus METH treatment. These data indicate that exposure to
METH, but not rotenone, is responsible for mobilizing intra-
cellular DA stores in PC12 cells, leading to DA depletion.
After confirming that METH was mobilizing DA stores, we
examined the effect of increased cytosolic DA on rotenone-
induced toxicity. We cotreated PC12 cells with 0.5 mM METH
and 0.5 µM rotenone, for 48 h, and measured cell viability
(Fig. 7B). In these studies, we utilized a lower concentration
of rotenone than in previous experiments, which led to a 22%
loss in viable cells. METH treatment alone also led to a small,
but significant decrease in cell viability (12% of control).
However, cotreatment of rotenone and METH led to a 49%
loss in cell viability, which was significantly different from
control, rotenone alone, and METH alone groups. In addition,
rotenone plus METH appeared to potentiate toxicity beyond
the sum of the toxicities seen in either treatment group alone.
To determine whether the effect was due to increased
cytosolic DA or due to a direct effect of METH, we first
depleted DA with AMPT and then treated PC12 cells with
METH and rotenone for 48 h. In this experiment, 0.5 mM
METH exposure led to only a 7% loss in viability, which was
not significantly different from control (Fig. 8). Rotenone
exposure (0.5 µM) led to a 29% loss in cell viability as com-
pared with control, which was again (as in Fig. 7) not signifi-
cantly different from rotenone treatment following DA deple-
tion with AMPT (34% as compared with control) (Fig. 8).
METH and rotenone cotreatment led to a 46% loss in cell
viability as compared with control, which was again signifi-
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FIG. 7. Effect of METH and rotenone cotreatment on
PC12 cell catechol levels and viability. PC12 cells were
treated with control medium, 0.5 mM METH, 0.5 µM rotenone,
or cotreated with 0.5 µM rotenone and 0.5 mM METH for 48 h.
(A) DA, DOPAC, and DOPA levels were determined using
HPLC with electrochemical detection. Data are expressed as
mean % control ± SEM (n = 4). *Statistically significant from
control, p < 0.05. (B) Cell viability was determined using try-
pan blue exclusion. Data are expressed as mean % control ±
SEM (n = 4). *Statistically significant from control, p < 0.05.
†Statistically significant from METH- and rotenone-alone
treated groups, p < 0.05.
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FIG. 8. Effect of DA depletion on METH and rotenone
cotreatment on PC12 cell viability. PC12 cells were treated
with control medium, 0.5 mM METH, 0.5 µM rotenone, pre-
treated with 1 mM AMPT for 3 days followed by 0.5 µM
rotenone treatment, cotreated with 0.5 µM rotenone and 0.5 mM
METH, or pretreated with 1 mM AMPT for 3 days followed by
0.5 µM rotenone and 0.5 mM METH cotreatment for 48 h. Cell
viability was then determined using trypan blue exclusion. Data
are expressed as mean % control ± SEM (n = 4). *Statistically
significant from control, p < 0.05. †Statistically significant
from METH- and rotenone-alone treated groups, p < 0.05.
‡Statistically significant from METH- and rotenone-cotreated
group, p < 0.05.
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cantly different from control, rotenone alone, and METH
alone treated groups (Fig. 8). However, 1,000 µM AMPT pre-
treatment followed by rotenone and METH cotreatment led
to attenuation of toxicity to only a 19% loss in viable cells,
which represents the rescue of 60% of the cells lost following
rotenone plus METH without pretreatment (Fig. 8). This ob-
servation suggests that a large portion of the enhanced toxic-
ity observed in rotenone/METH-induced toxicity could be
due to the presence of DA.
DISCUSSION
In the present study, we wanted to determine the role of
DA in rotenone-induced toxicity, to understand better the
possible contribution of DA to cell death in PD. Oxidative
stress and mitochondrial dysfunction, combined with DA
oxidation, may make dopaminergic cells a more vulnerable
target for toxic stimuli in PD. The rotenone model, with Com-
plex I inhibition and selective dopaminergic cell death, pos-
sesses many aspects of PD pathology, including evidence of
increased oxidative stress (47) and -synuclein-positive pro-
tein aggregates (48). Therefore, we used rotenone, in con-
junction with AMPT and METH, to examine the contribution
of DA to rotenone-induced toxicity in PC12 cells. We found
that DA depletion prior to toxin exposure did not protect
against rotenone-induced toxicity. However, rotenone toxicity
was potentiated in PC12 cells by the intracellular release of
DA from the vesicles, induced by METH exposure. 
Partial inhibition of Complex I has been shown to increase
mitochondrial production of ROS (38, 57), which may be the
precipitating event in toxicity models. However, the basis for
rotenone-induced selective toxicity to dopaminergic neurons
remains ambiguous. The increased oxidative stress within
dopaminergic neurons, due to DA metabolism and oxidation,
combined with enhanced ROS production by Complex I inhi-
bition may lead to cell death by overloading the antioxidant
capacity of these cells. In addition, DA oxidation may cause
mitochondrial dysfunction, because isolated mitochondria
exposed to DAQ have increased state 4 (uncoupled) respi-
ration and opening of the permeability transition pore (4).
DA oxidation, mitochondrial dysfunction, and mitochondrial
ROS production are all processes that can lead to an increas-
ing cascade of oxidative damage to cellular macromolecules,
which may lead to total mitochondrial failure and cell death.
We found that the depletion of DA by AMPT did not pro-
tect PC12 cells from rotenone-induced toxicity. However,
coexposure of PC12 cells to rotenone and METH, which
leads to the release of DA stores into the cytoplasm, led to
increased toxicity. Additionally, the potentiation of rotenone
toxicity by METH was blocked when PC12 cells were de-
pleted of DA prior to rotenone and METH cotreatment. Al-
though METH may have toxic actions on its own (8), these
data suggest that cytoplasmic DA, and perhaps increased ox-
idative stress due to DA oxidation and metabolism, may exac-
erbate rotenone-induced toxicity in differentiated PC12 cells.
Previous studies in primary mesencephalic cultures (41),
SH-SY5Y cells (46), and undifferentiated PC12 cells (19)
have shown nanomolar concentrations of rotenone to be
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toxic. However, in this study, we found a 37–70% decrease
in cell viability in NGF-differentiated PC12 cells following a
48-h exposure to 0.5–20 µM rotenone (Fig. 1), and very little
toxicity prior to 48 h (data not shown). Differentiated PC12
cells seem to be less susceptible to rotenone-induced toxicity
than other cellular models, which may be due to the presence
of the growth factor NGF throughout exposure.
ATP levels were depleted following 1 µM rotenone ex-
posure (Fig. 2). However, the levels of ATP after 24 h of
rotenone treatment (75% of control) were higher than the
ATP levels following 12 h (40% of control) or 48 h (35% of
control) of rotenone exposure. The jump in ATP levels may
be the result of glycolysis stimulated by rotenone-induced
Complex I inhibition. PC12 cells have previously been shown
to resort to increased glycolysis when challenged with the
mitochondrial Complex I inhibitor, MPP+ (26). This has also
been observed in primary neuronal cultures in response to
oxidative stress (3). Our observations suggest that the com-
plete loss of ATP was not responsible for cell death, as also
determined by others (50).
Rotenone-induced catecholamine release in PC12 cells has
been previously observed (54), and in our study, we observed
a slight, but significant, depletion of DA following a 6–24-h
treatment with 1 µM rotenone (Fig. 3). However, at 24 h,
a lower concentration of rotenone (0.5 µM) did not affect
DA levels (Fig. 7A). Therefore, if DA is being released from
PC12 cells following rotenone treatment, it is very small com-
pared with the total DA stored in the cells. We also observed a
substantial decrease in DOPAC levels in PC12 cells treated
with rotenone (Figs. 3 and 7A), but found no direct effect
of rotenone on MAO activity in isolated mitochondria. De-
creased DOPAC levels have been previously observed in PC12
cells following rotenone treatment (27). Decreased DOPAC
following rotenone in that study was accompanied by in-
creased levels of 3,4-dihydroxyphenylacetaldehyde (DOPAL),
suggesting that rotenone leads to the inactivation of alde-
hyde dehydrogenase, the enzyme that converts DOPAL into
DOPAC (27). DOPAL exposure has been shown previously
to be toxic to dopaminergic cells (33), and thus may add to
the rotenone-induced toxicity. However, we did not observe
the presence of DOPAL in PC12 cells following rotenone
treatment. We also observed increased DOPA levels following
rotenone treatment (Figs. 3 and 7A). DOPA-induced toxicity
has previously been shown in PC12 cells (1). Like DA, DOPA
can oxidize, forming ROS and DOPA quinones, which could
add to the oxidative damage in the cell (16).
Rotenone has been shown to increase oxidative stress. In
previous cell culture studies, rotenone reduced GSH levels
(45, 47), while increasing levels of oxidized glutathione
(GSSG) (45). In addition, acute and chronic rotenone expo-
sure in SK-N-MC cells leads to increased carbonyl formation
(47, 50). In this study, we observed evidence of increased
DA oxidation following rotenone treatment in PC12 cells,
as levels of protein cysteinyl-DA and cysteinyl-DOPAC in-
creased after 12–48 h of rotenone exposure (Fig. 4), sugges-
tive of an oxidative environment in the cells.
Previous studies have shown that depletion of DA is pro-
tective in MPP+-induced toxicity (30), and recent studies in
primary mesencephalic cultures have suggested that DA may
be involved in rotenone-induced toxicity (41). In addition,
13910C11.pgs  4/5/05  4:35 PM  Page 635
rotenone potentiated amphetamine-induced toxicity in pri-
mary mesencephalic cultures, which was also thought to be
due to DA (31). We found that DA depletion did not affect
rotenone-induced toxicity in PC12 cells (Fig. 6). However, as
DA may not have been accessible for oxidation due to PC12
cell’s high storage capacity, we utilized a way to mobilize en-
dogenous DA stores in the presence of rotenone, to determine
whether DA could play a role in rotenone-induced toxicity.
Previous studies have shown that METH is transported into
cells by DAT (15), where it displaces vesicular DA into the
cytoplasm (9), leading to DA depletion (15). In PC12 cells,
METH treatment and rotenone/METH cotreatment led to DA
depletion (Fig. 7A), suggesting that DA was being released
from the vesicles into the cytoplasm, where it could be easily
oxidized, metabolized, and/or released from the cell via rever-
sal of DAT. Results showed that DA potentiates rotenone-
induced toxicity following the mobilization of DA by METH
(Fig. 7B), an effect that was eliminated with prior DA de-
pletion (Fig. 8). METH has also been shown to enhance 3-
nitropropionic acid and glutamate toxicity (for review, see
24), an effect thought to be dependent on DA. Although oxi-
dative stress is likely to be involved, the mechanism may be
different from the intracellular effects on DA neurons.
Rotenone and other Complex I inhibitors are currently
being used as PD models both in vivo and in vitro (17). How-
ever, the question of why Complex I inhibitors seem to tar-
get dopaminergic neurons has remained unanswered. The
present study demonstrates that unsequestered, intracellular
DA could play a significant role in the selective targeting
of DA neurons in rotenone-induced toxicity. The ability of
a dopaminergic cell to deal with increased oxidative stress,
created by Complex I inhibition, may be hampered by the
presence of DA, which may further increase oxidative stress.
The Complex I deficiency observed in PD is likely to cause
increased ROS production, which in turn will promote DA
oxidation, leading to a cycle of increasing oxidative stress
and further DA oxidation. This will result in oxidative protein
modifications, inactivation of critical protein functions, and/
or altered protein degradation, all of which are likely to con-
tribute to the pathological mechanisms involved in PD. 
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PD, Parkinson’s disease; ROS, reactive oxygen species; TH, ty-
rosine hydroxylase.
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